Hardman Johnston Global Advisors LLC Has $18.97 Million Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Hardman Johnston Global Advisors LLC boosted its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 22.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 1,566,430 shares of the company’s stock after purchasing an additional 288,160 shares during the quarter. Hardman Johnston Global Advisors LLC’s holdings in Elanco Animal Health were worth $18,969,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ELAN. AM Squared Ltd acquired a new position in shares of Elanco Animal Health during the 3rd quarter worth approximately $34,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Elanco Animal Health during the 3rd quarter worth approximately $35,000. Farther Finance Advisors LLC increased its holdings in shares of Elanco Animal Health by 158.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock worth $49,000 after acquiring an additional 2,044 shares during the last quarter. Venturi Wealth Management LLC increased its holdings in shares of Elanco Animal Health by 89.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock worth $50,000 after acquiring an additional 1,601 shares during the last quarter. Finally, Blue Trust Inc. increased its holdings in shares of Elanco Animal Health by 2,129.2% during the 3rd quarter. Blue Trust Inc. now owns 3,968 shares of the company’s stock worth $57,000 after acquiring an additional 3,790 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 1.0 %

Shares of Elanco Animal Health stock opened at $11.02 on Monday. Elanco Animal Health Incorporated has a one year low of $10.77 and a one year high of $18.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The stock’s 50-day moving average is $11.80 and its 200 day moving average is $13.10. The firm has a market cap of $5.45 billion, a price-to-earnings ratio of 27.54, a PEG ratio of 2.50 and a beta of 1.42.

Analyst Ratings Changes

ELAN has been the topic of a number of recent analyst reports. Barclays boosted their target price on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. Morgan Stanley decreased their target price on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 29th. Stifel Nicolaus decreased their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Friday. Leerink Partners began coverage on Elanco Animal Health in a report on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price on the stock. Finally, Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $16.00.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.